Institutional shares held 126 Million
3.29M calls
2.01M puts
Total value of holdings $6.58B
$172M calls
$105M puts
Market Cap $4.85B
94,144,096 Shares Out.
Institutional ownership 133.69%
# of Institutions 409


Latest Institutional Activity in CYTK

Top Purchases

Q3 2024
Verde Servicos Internacionais S.A. Shares Held: 36.3K ($1.87M)
Q3 2024
Harbor Capital Advisors, Inc. Shares Held: 42.5K ($2.19M)
Q3 2024
Van Eck Associates Corp Shares Held: 71.7K ($3.69M)
Q3 2024
Alpha Centric Advisors LLC Shares Held: 12.5K ($644K)
Q3 2024
International Assets Investment Management, LLC Shares Held: 10.6K ($544K)

Top Sells

Q3 2024
Sg Americas Securities, LLC Shares Held: 22.2K ($1.14M)
Q3 2024
Moody Aldrich Partners LLC Shares Held: 46.7K ($2.41M)
Q3 2024
Abrdn PLC Shares Held: 348K ($17.9M)
Q3 2024
New York State Common Retirement Fund Shares Held: 34.6K ($1.78M)
Q3 2024
Yousif Capital Management, LLC Shares Held: 44.3K ($2.28M)

About CYTK

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy; and CK-3772271, a small molecule cardiac myosin inhibitor that is in Phase I clinical trial. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.


Insider Transactions at CYTK

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
594K Shares
From 20 Insiders
Grant, award, or other acquisition 219K shares
Exercise of conversion of derivative security 374K shares
Sell / Disposition
565K Shares
From 14 Insiders
Open market or private sale 493K shares
Payment of exercise price or tax liability 69.8K shares
Bona fide gift 2.11K shares

Track Institutional and Insider Activities on CYTK

Follow CYTOKINETICS INC and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells CYTK shares.

Notify only if

Insider Trading

Get notified when an Cytokinetics Inc insider buys or sells CYTK shares.

Notify only if

News

Receive news related to CYTOKINETICS INC

Track Activities on CYTK